TSE:4528Pharmaceuticals
Does Ono’s Phase 3 Sapablursen Trial in Polycythemia Vera Reshape The Bull Case For Ono Pharmaceutical (TSE:4528)?
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical, recently dosed the first patient in INTREPID, a global pivotal Phase 3 trial of sapablursen for polycythemia vera, a rare and potentially life‑threatening blood disease.
This milestone highlights Ono Pharmaceutical’s push to expand its pipeline in rare hematologic conditions with an investigational once‑monthly treatment approach that could address meaningful unmet medical needs.
We’ll now explore how progress in this Phase 3...